Yahoo Finance5d
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) as the US Food and Drug Administration (FDA ...
Yahoo Finance6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
September 18, 2024--(BUSINESS WIRE)--AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
FiercePharma6d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 inhibitors have engaged in a spirited market battle, with one key ...
Stockhouse6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s FASENRA ...
Investing6d
FDA approves Fasenra for rare vasculitis treatment
WILMINGTON, Del. - AstraZeneca’s Fasenra (benralizumab) has gained U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with eosinophilic granulomatosis with ...
PharmiWeb6d
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
The safety and tolerability profile for Fasenra in the MANDARA trial was consistent with the known profile of the medicine. 4 Approximately half of patients with EGPA have adult-onset severe ...
Pharmabiz5d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
London South East6d
AstraZeneca Fasenra treatment for EGPA approved in the US
(Alliance News) - AstraZeneca PLC on Wednesday announced Fasenra has been approved in the US to treat adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA. The Cambridge ...
Investing6d
FDA approves Fasenra for rare vasculitis treatment
WILMINGTON, Del. - AstraZeneca’s Fasenra (benralizumab) has gained U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with eosinophilic granulomatosis with ...
Benzinga.com6d
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
In the trial, nearly 60% of Fasenra-treated patients achieved remission, comparable to GSK's mepolizumab-treated patients. Fasenra is currently approved as an add-on maintenance treatment for ...